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Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disease caused
by expansion of a CTG trinucleotide repeat in the DMPK gene. Methodology for genetic
testing of DM1 is currently not optimal, in particular for the early-onset patients in pediatric
populations where large expanded (CTG)n alleles are usually common. Individuals who are
homozygous for a normal allele and individuals who are heterozygous for one normal and
one large expanded allele are indistinguishable by conventional PCR, as both generate a
single product of the normal allele. Thus, reﬂex Southern blot has often been needed to
distinguish these cases.With the aim to decrease the need for reﬂex Southern blot tests, a
novel, single-tube CTG repeat primed PCR technology was designed to distinguish the true
homozygous patients from the individuals whose large alleles are missed by conventional
PCR. The method utilizes two gene-speciﬁc primers that ﬂank the triplet repeat region
and a third primer set complementary to the repeated region to detect the large alleles.
Compared to traditional PCR, this novelTriplet-repeat Primed PCR can detect the presence
of large expanded alleles with demonstrating a ladder pattern. Using this single-step
protocol, 45 specimens were tested.The alleles with sizes ≤ 85 repeats were determined
by the gene speciﬁc primers. 13 abnormal alleles, whichweremissed by conventional PCR,
were successfully detected by theTriplet-repeat Primed PCR. All the abnormal alleles were
conﬁrmed and measured by Southern Blot analysis. In summary, optimizedTriplet-Primed
PCR (TP-PCR) can accurately detect the presence of the large expanded alleles. With the
ability to distinguish the true homozygous patients from the false negative homozygous
individuals, the application of the optimized TP-PCR can signiﬁcantly reduce the need of
Southern Blot tests.
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INTRODUCTION
Mytonic dystrophy type 1(DM1) is the most common adult
onset neuromuscular disorder, with a prevalence frequency rang-
ing from 1 to 15 in 100,000, and is inherited in an autosomal
dominant pattern (Turner and Hilton-Jones, 2010). DM1 is a
multisystem disorder that widely effects skeletal and smooth mus-
cle, the endocrine system, the eye, heart and central nervous
system (Johnson and Heatwole, 2012). The clinical indications
span from mild to severe. DMPK is the only reported gene
in which mutations cause DM1. DMPK is located on chro-
mosome 19q13.3, and encodes a serine-threonine kinase. The
disease causing mutation is an unstable CTG triplet expansion
in the 3′-untranslated region of the DMPK gene (Prior, 2009).
In normal individuals, the number of CTG repeats ranges from
5 to 34. Individuals with 35 to 49 CTG repeats have not been
reported to develop DM1, but the number of the CTG repeats
may increase when this allele is passed on to the next gener-
ation. People are affected with DM1 if the number of CTG
repeats is equal to or greater than 50 (Bird, 2013). The severity
of symptoms in DM1 is correlated with the repeat size. Patients
with congenital or severe DM1 tend to have thousand(s) of CTG
repeats in the 3′UTR region of the DMPK gene (Zeesman et al.,
2002).
The molecular diagnostic analysis of DM1 is to determine
the number of CTG repeats in two alleles with fragment-length
based techniques, such as PCR or Southern Blot (Prior, 2009).
Conventional PCR can detect a lower range of DM1 expansions,
thus covering the normal and premutated alleles. Optimized
PCR conditions can detect full penetrance alleles with a size
up to 85 CTG repeats. Detection of the larger expansions still
has relied on Southern Blot. Compared to PCR-based clinical
laboratory techniques, Southern Blot has drawbacks. The require-
ment of large amounts of DNA and use of radioactive materials
makes this procedure time consuming while demonstrating low
sensitivity. In order to develop an efﬁcient and sensitive molecu-
lar method, Triplet-Primed PCR (TP-PCR) was ﬁrst introduced
for detection of large CTG repeat expansions by Warner et al.
(1996). TP-PCR provides an advantage in rapidly identifying the
large pathogenic CTG repeats. The aims of this study were to
verify the validity of TP-PCR for the diagnosis of patients pre-
senting with DM1 clinical ﬁndings and to simplify the testing
procedure.
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MATERIALS AND METHODS
STUDY SUBJECTS
A total of 45 samples were retrospectively analyzed, including 19
patients and 26 proﬁciency testing survey (PTS) samples. The
patients were selected from previous clinical samples from 2008 to
2013. The PTS samples were selected from 2008 to 2013. The sam-
ple population represents a range of CTG sizes covering normal,
mild abnormal, and classic mutants. An IRB protocol (protocol
# 1401263105) was approved by the Human Subjects Ofﬁce at
Indiana University.
CONVENTIONAL PCR
Genomic DNA was extracted from peripheral blood using the
DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD, USA).
Conventional PCR was performed with 100 ng of genomic DNA
using gene speciﬁc primers ﬂanking the DMPK CTG repeat (For-
ward: DM101 5′ FAM-CTT CCCAGG CCT GCAGTT TGC CCA
TC 3′ and Reverse: DM102 5′ GAA CGG GGC TCG AAG GGT
CCT TGT AGC 3′; Gharehbaghi-Schnell et al., 1998). All normal
homozygotes and expanded alleles were conﬁrmed with Southern
Blot.
TRIPLET-REPEAT PRIMED PCR
Compared to the reported two-step procedure TP-PCR, in
our study the triplet primed PCR was modiﬁed to a single-
tube PCR reaction. The modiﬁed TP-PCR was performed with
100 ng of genomic DNA in a reaction volume of 25 μl.
FAM-P1-Forward and P2-Reverse are designed as the gene spe-
ciﬁc PCR primers ﬂanking the CTG repeat region (FAM-P1-
Forward: 5′FAM-GGG-GCT-CGA-AGG-GTC-CTT-GT-3′ and
P2-Reverse: 5′-GTG-CGT-GGA-GGA-TGG-AAC-ACG-3′). The
forward primer was labeled with FAM ﬂuorescence. Primer P4-
(CAG)6-Reverse consists of two parts: a 3′-end with 6 CAG
repeats and a 5′-end containing a universal sequence [P4-
(CAG)6-Reverse: 5′AGC-GGA-TAA-CAA-TTT-CAC-ACA-GGA-
CAG-CAG-CAG-CAG-CAG-CAG-3′]. P4-(CAG)6-Reverse can
anneal to random complementary regions of theCTG trackwithin
the DMPK gene (Figure 1). The universal tail does not repre-
sent any homology to the human genome. P3 was designed to
bind to the complement of the tail of the P4-(CAG)6-Reverse (P3:
5′AGC-GGA-TAA-CAA-TTT-CAC-ACA-GGA- 3′). The combi-
nation of primers was prepared in a ratio as: FAM-P1-Forward:
P4-(CAG)6-Reverse:P3:P2-Reverse = 1.5:1:1.5:1.5, with a ﬁnal
working concentration of 0.6 μM:0.4 μM:0.6 μM: 0.6 μM. The
modiﬁed Triplet-repeat Primed PCR was performed in a 25 μl
volume using the FailSafeTM PCR system (Madison, WI 53719,
USA). The reactions were subjected to 1 cycle of 95◦C for 5 min,
and 10 cycles of 97◦C for 35 s, 65◦C for 35 s and 68◦C for
4 min, followed by 20 cycles in which the extension time was
increased by 20 s per cycle to allow for increased yield of PCR
product. TP-PCR was repeated with Hex labeled P2-Reverse
to rule out any false negative results from CAG interruptions.
The sequence information of the TP-PCR primers is listed in
Table 1.
PCR PRODUCT ANALYSIS ON GENETIC ANALYZER
Products were separated on an ABI PRISM 3130 × l genetic ana-
lyzer (Life Tech, Grand Island, NY 14072, USA). 1 μl of PCR
product was mixed with 0.5μl of MapMarker ROX 1000 (Bioven-
tures, Murfreesboro, TN, USA) and 9 μl of HiDi Formamide (Life
Tech, Grand Island, NY 14072, USA). The mixture was denatured
at 95◦C for 5 min then loaded onto the 3130 × l genetic analyzer.
FIGURE 1 |The principle of the modifiedTP-PCR.Two PCR procedures,
conventional PCR andTP-PCR are simultaneously carried out. The
conventional PCR primers, P1-F and P2-R bind to the gene speciﬁc regions
that closely ﬂank the CTG repeat, generating the smaller alleles. Primer
P4(CTG)6-R has two parts: 6 CAG trinucleotides at the 3′-end sequence and
an artiﬁcial sequence with no homology to the human genome at the 5′-end
sequence. By the triplet priming from its 3′-end sequence, a ladder of PCR
fragments differing by 1 CTG unit is produced.
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Table 1 |Triplet-Primed PCR primer sequences.
Primer name Primer sequence
Forward direction TP-PCR FAM-P1-forward 5′FAM-GGG-GCT-CGA-AGG-GTC-CTT-GT-3′
P4-(CAG)6-reverse 5′AGC-GGA-TAA-CAA-TTT-CAC-ACA-GGA-CAG-CAG-CAG-CAG-CAG-CAG-3′
P3 5′AGC-GGA-TAA-CAA-TTT-CAC-ACA-GGA- 3′
P2-reverse 5′-GTG-CGT-GGA-GGA-TGG-AAC-ACG-3′
Reverse direction TP-PCR P1-forward 5′-GGG-GCT-CGA-AGG-GTC-CTT-GT-3′
P4(CTG)6-forward 5′AGA-GGA-TAA-CAA-TTT-CAC-ACA-GGA-TGC-TGC-TGC-TGC-TGC-TGC-TG-3′
P3 5′AGC-GGA-TAA-CAA-TTT-CAC-ACA-GGA- 3′
Hex-P2-reverse 5′Hex-GTG-CGT-GGA-GGA-TGG-AAC-ACG-3′
Fragment size was analyzed using GeneMarker V2.6 (Softgenetics,
State College, PA, USA).
SOUTHERN BLOT
With the purpose to conﬁrm and measure the abnormal alleles,
Southern Blots tests were performed in the samples indicating one
normal allele by PCR. 47 μg of genomic DNA was digested with
Bgl 1 restriction enzyme. The digestedDNAwas separated on a 1%
agarose gel at 60 volts for 18 h. The gel was depurinated, denatured,
neutralized, and DNA was transferred to a positive nitrocellulose
membrane (Biodyne B 0.45UM, VWR, PA 19087, USA). After
transfer, the membrane was hybridized with 32P labeled DM1
probe and exposed with X-ray ﬁlm (Kodak, Rochester, NY, USA)
overnight or longer as appropriate.
RESULTS
Forty ﬁve samples had been previously tested with conventional
PCR and reﬂex Southern blot. Of those 45, 24 gave two distinct
allele peaks by PCR. 23 of the 24 samples had two normal alle-
les and one sample showed one normal allele and one abnormal
allele with a CTG repeat size of 85 repeats. The 85 repeat allele is
the largest detected by conventional PCR and sizable by TP-PCR.
21 patients had only one peak with the repeat size falling in the
normal range. Southern Blot was performed as a reﬂex test and
an expanded band was detected in 13 of the 21 samples. These
large alleles were missed by conventional PCR and ranged from
150 CTG repeats to 1700 repeats.
To validate an efﬁcient clinical technique to detect the pres-
ence of the large alleles and reduce the use of the Southern Blot
test, a modiﬁed TP-PCR was utilized with the same sample set.
In this study, the TP-PCR was modiﬁed from a two-tube reac-
tion to a one-tube reaction. With a combination of one set of
gene speciﬁc primers and one hybrid triplet primer, the TP-PCR is
capable of amplifying normal alleles and screening expanded alle-
les in one tube reaction. The normal allele sizes from the TP-PCR
indicated good concordance with the conventional PCR (Table 2).
Of 13 abnormal samples missed by conventional PCR, a ladder
pattern was found indicating the presence of an expanded allele
(Figure 2). Thus, by screening with TP-PCR, only 13 of 21 samples
that had one allele with conventional PCR would need the South-
ern Blot test. The need for the reﬂex test is reduced by 38.1%.
The detection rate for the abnormal alleles is 100%. In order
to rule out false negative results due to the CCG, CTC, or GGC
interruptions, TP-PCR was also performed with a HEX- labeled
P2-Reverse primer. The P2-Reverse primer gave a consistent, one
triplet repeat smaller size than that indicated by the FAM-labeled
TP-PCR (Table 2).
DISCUSSION
Clinical testing of the CTG expansion remains a challenge due
to the large repeat size, especially in classical or congenital DM1
patients. The traditional method applied in the molecular diag-
nosis of DM1 is currently conventional PCR in conjunction with
Southern Blot to detect and measure the large expansions. Con-
ventional PCR is used as the ﬁrst step to determine alleles with
a low number of repeats. Due to the limitations of conventional
PCR, true homozygous normal patients cannot be differentiated
from the heterozygous patients with one normal and one large
expanded allele. Thus, if only one allele is ampliﬁed from conven-
tional PCR, a subsequent test, Southern Blot, is used to test for
possible larger expansions. This makes the molecular diagnosis of
DM1 complicated and time consuming.
TP-PCR was ﬁrst introduced by Warner et al. (1996) and was
advantageous in the reduced need to perform Southern Blot.With
TP-PCR, the true homozygotes and false negative homozygotes
can be distinguished based on the presence or absence of an
expanded triplet ladder pattern. After TP-PCR screening, only
patients displaying a laddering tail will receive a reﬂex South-
ern blot test. It signiﬁcantly reduces the need of the Southern
Blot test. In our study, the application of TP-PCR decreased this
need by 38.1%. However, the previous reported TP-PCR cannot
provide genotyping information. An additional regular PCR step
is required to size the normal and small expanded alleles. The
genotyping of the large alleles still has to rely on Southern blot.
An improved TP-PCR had been reported in the molecular
diagnosis of Fragile X (Tassone et al., 2008; Chen et al., 2010).
They developed a single-tube CGG repeat primed FMR1 PCR
test that can detect the full range of FMR1 expanded alleles.
This method includes one set of gene speciﬁc primers plus one
chimeric PCR primer that targets randomly within the expanded
CGG region. According to their report, the method is able to
size expansions/alleles up to 200 CGG repeats and detect full-
mutation ranges from one single test. In our studies, in order to
simplify the testing procedure and reduce the cost, we combined
the conventional ﬂuorescent PCR and TP-PCR into a one-tube
multiplex PCR. A second gene speciﬁc primer pairing to P1 was
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Table 2 | CTG size information obtained fromTriplet-repeat Primed PCR, conventional PCR and Southern Blot.
Results fromTriplet Primed PCR Results from conventional PCR and Southern Blot
Sample ID CTG number, FAM
labeled-forward primer
CTG number, HEX
labeled-reverse primer
Detection of
expanded allele
CTG number, FAM
labeled-forward primer
CTG number, convention PCR
with reflex Southern Blot
DM-1 5 4 No 5 5
DM-2 5/85* 4/84* Yes 5/85* 5/85*
DM-3 5 4 Yes 5 5/700*
DM-4 11/12 10/11 No 11/12 11/12
DM-5 13/14 12/13 No 13/14 13/14
DM-6 12 11 No 12 12
DM-7 13 12 No 13 13
DM-8 13 12 No 13 13
DM-9 21 20 No 20 20
DM-10 12/13 11/12 No 12/13 12/13
DM-11 5 4 Yes 5 5/1300–1700*
DM-12 12/13 11/12 No 11/12 11/12
DM-13 12 11 Yes 11 11/700–1700*
DM-14 14 13 Yes 13 13/1800*
DM-15 5 4 Yes 4 4/150–450*
DM-16 11/12 10/11 No 10/11 10/11
DM-17 11/13 10/12 No 11/12 11/12
DM-18 12/13 11/12 No 10/11 10/11
DM-19 5 4 No 4 4
DM-20 10/16 9/15 No 10/16 10/16
DM-21 12 11 Yes 12 12/350*
DM-22 5/12 4/11 No 5/12 5/12
DM-23 12 11 Yes 12 12/550*
DM-24 12/13 11/12 No 12/13 12/13
DM-25 10/16 9/15 No 10/16 10/16
DM-26 21 20 Yes 21 21
DM-27 5/13 4/12 No 5/13 5/13
DM-28 12/13 11/12 No 12/13 12/13
DM-29 12 11 Yes 11 11/380*
DM-30 5/11 4/10 No 5/10 5/10
DM-31 5/12 4/11 No 4/11 4/11
DM-32 5/13 4/12 No 4/12 4/12
DM-33 12 11 Yes 11 11/600*
DM-34 5/13 4/12 No 4/12 4/12
DM-35 10/16 9/15 No 9/15 9/15
DM-36 12/13 11/12 No 11/12 11/12
DM-37 12 11 Yes 11 11/350*
DM-38 10/16 9/15 No 9/15 9/15
DM-39 13/20 12/19 No 12/19 12/19
DM-40 12/14 11/13 No 11/13 11/13
DM-41 12 11 Yes 11 11/409*
DM-42 12 11 Yes 11 11/350*
DM-43 5/11 4/10 No 4/10 4/10
DM-44 5 4 No 4 4
DM-45 12 11 Yes 11 11/634*
*indicates an expanded allele.
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FIGURE 2 | Electropherogram results ofTP-PCR. X-axis illustrates the CTG
repeat number. Y-axis illustrates the allele peak height. (A) Electropherogram
of DM1 genotyping of a sample showing alleles of 14/57 CTG repeats.
(B) Electropherogram result of a sample with a normal allele was determined
with a size of 12 CTG repeats. In addition to the normal allele, a ladder signal
was represented byTP-PCR indicating the existence of an expanded allele
(see enlarged insert). (C) Demonstrates two normal heterozygous alleles
(13/14) and no laddering signal from theTP-PCR (see enlarged insert).
introduced at an optimized ratio that allowed the ampliﬁcation
of the normal and mutable alleles. The modiﬁed TP-PCR is still
able to detect the expanded mutants and size the normal or
premutated alleles in one single reaction (Figure 2). Therefore,
conventional PCR is not required to size the normal alleles in the
DM1 patients.
The presence of CCG interruptions could potentially lead to
the drop-out of the abnormal allele from TP-PCR (Santoro et al.,
2013). In order to avoid the false negative results due to CCG
interruptions, TP-PCR is recommended to be performed in both
directions with two different ﬂuorescent dyes. In our study, the
TP-PCR was performed from both the forward and reverse direc-
tions in 45 samples (FAMTP-PCR andHEXTP-PCR). The testing
results demonstrated good concordance with previous results for
the 45 samples. Alleles sized by the HEX TP-PCR consistently dis-
played one CTG repeat smaller than the FAM labeled amplicons.
This size difference is reported to be from the mobility shift vari-
ance resulting from the structure of ﬂuorescent dyes and different
composition of the single-stranded DNA (Radvansky et al., 2011).
All eight samples that were indicated to be normal homozygotes
with FAM TP-PCR were also indicated to be normal homozygotes
with HEX TP-PCR. This helps rule out false negatives generated
from CCG interruptions.
In conclusion, the modiﬁed bidirectional TP-PCR test is capa-
ble of differentiating normal, premutated, and fully mutated
alleles in DMPK. It improves the traditional TP-PCR by enabling
reduction from two PCR procedures to one PCR procedure. The
modiﬁed TP-PCR can accurately detect the presence of the large
expanded allele and signiﬁcantly reduce the need of the South-
ern Blot test. It is simple, sensitive, and reliable for clinical testing
of DM1 patients and can be an efﬁcient screening method in the
clinical diagnosis of myotonic dystrophy type 1.
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